Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study. (17th May 2013)

• Record Type: Journal Article
• Authors: Papp, K.A.; Sundaram, M.; Bao, Y.; Williams, D.A.; Gu, Y.; Signorovitch, J.E.; Wang, Y.; Valdes, J.M.; Mulani, P.M.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 28:Number 6(2014:Jun.)
• Page Start: 790
• Page End: 798
• Publication Date: 2013-05-17
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.12177
• Languages: English
• ISSNs: 0926-9959

Abstract

<abstract abstract-type="main" id="jdv12177-abs-0001"> <title>Abstract</title> <sec id="jdv12177-sec-0001" sec-type="section"> <title>Background</title> <p>Psoriasis is known to have a significant negative impact on a patient's health‐related quality of life, including social, recreational and work activities.</p> </sec> <sec id="jdv12177-sec-0002" sec-type="section"> <title>Objective</title> <p>To evaluate the effects of briakinumab on quality of life and work productivity measures in patients with moderate to severe psoriasis.</p> </sec> <sec id="jdv12177-sec-0003" sec-type="section"> <title>Methods</title> <p>Patients received either briakinumab (<italic>n</italic> = 981) or placebo (<italic>n</italic> = 484) during the 12‐week induction phase of trial M06‐890. At week 12, patients with a Physician's Global Assessment score of 'Clear' or 'Minimal' entered the 40‐week maintenance phase and were to receive briakinumab every 4 weeks, briakinumab every 12 weeks, or placebo. At weeks 12 and 52, treatment groups were compared using mean change from baseline in health‐related quality of life and Work Productivity and Activity Impairment Questionnaire scores and the percentage of patients with minimum clinically important differences.</p> </sec> <sec id="jdv12177-sec-0004" sec-type="section"> <title>Results</title> <p>At week 12, more than half of the briakinumab‐treated patients achieved improvements meeting or exceeding minimum clinically important differences for Dermatology Life Quality Index (75.9%), and psoriasis‐ (64.8%), and psoriatic arthritis‐related (54.1%) pain scores; 48.4% achieved improvements for activity impairment. Although improvements in quality of life and work productivity measures were maintained at week 52 for both briakinumab regimens, responder rates were consistently greater in the every‐4‐week group than in the every‐12‐week group.</p> </sec> <sec id="jdv12177-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Briakinumab treatment resulted in clinically significant improvements in quality of life and work productivity in adults with moderate to severe psoriasis. Maintenance therapy was associated with a more pronounced benefit for the every‐4‐week briakinumab regimen.</p> </sec> </abstract>